Content and Copyright
-
- Add this to...
-
Twitter
-
Facebook
-
Google Bookmarks
-
LinkedIn
Fragile X Syndrome and Targeted Treatment Trials
-
Published Date:2012
-
Publisher's site:
-
Source:Results Probl Cell Differ. 2012; 54:297-335.
-
[PDF-152.73 KB]
Details:
-
Alternative Title:Results Probl Cell Differ
-
Personal Author:
-
Description:Work in recent years has revealed an abundance of possible new treatment targets for fragile X syndrome (FXS). The use of animal models, including the fragile X knockout mouse which manifests a phenotype very similar to FXS in humans, has resulted in great strides in this direction of research. The lack of Fragile X Mental Retardation Protein (FMRP) in FXS causes dysregulation and usually overexpression of a number of its target genes, which can cause imbalances of neurotransmission and deficits in synaptic plasticity. The use of metabotropic glutamate receptor (mGluR) blockers and gamma amino-butyric acid (GABA) agonists have been shown to be efficacious in reversing cellular and behavioral phenotypes, and restoring proper brain connectivity in the mouse and fly models. Proposed new pharmacological treatments and educational interventions are discussed in this chapter. In combination, these various targeted treatments show promising preliminary results in mitigating or even reversing the neurobiological abnormalities caused by loss of FMRP, with possible translational applications to other neurodevelopmental disorders including autism.
-
Subject:
-
Pubmed ID:22009360
-
Pubmed Central ID:PMC4114775
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
Supporting Files:
text/plain
No Related Documents.
You May Also Like:
-
Published Date:Source:Description:Public Access Available on: -
Published Date:Source:Description:Public Access Available on:
-
Published Date:Source:Description:Public Access Available on:
-
-
